Skip to main content
Clinical Trials/NCT00568867
NCT00568867CompletedNot Applicable

Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample

Stanford University1 site in 1 country300 target enrollmentStarted: September 2006Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
300
Locations
1

Study Overview

Brief Summary

The purpose of this study is to evaluate markers of immune response in human tumor samples.

Detailed Description

Cancer immunotherapy has been shown to be effective in isolated instances, but ineffective in most patients. The reason for this inconsistency, and the conditions necessary for successful immunotherapy, are not well understood. Our studies in animal tumor models indicate that the effectiveness of IL-12-based immunotherapy depends upon the presence of a preexisting immune response to the tumor. The presence of T cell infiltrates and IFN-gamma expression in tumor indicate such an immune response. We therefore plan to evaluate the existing immune response in human tumor samples in an effort to identify those patients most likely to respond to therapy with IL-12.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Any adult patient with a tumor who is scheduled to undergo surgery to either remove or biopsy the tumor.

Exclusion Criteria

  • Patients without tumor and pediatric patients (children) will be excluded.

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Evaluation of Preexisting Immunity Markers... | Clinical Trial